Manchester City And Xylem Call On Football Fans To Vote For Young Water Heroes Tackling Global Water Issues
Manchester City Football Club’s global community program, Cityzens Giving, and global water technology leader, Xylem (NYSE: XYL) are calling on football fans to vote for their top project as the Water Heroes Academy returns for a second year. From November 22 to December 5, fans from around the world can vote for one of five new football and water projects from young leaders working to tackle global water issues in Buenos Aires, Cape Coast, Kuala Lumpur, Melbourne, and Mexico City.
Young leaders involved in this year’s program are using the power of football to provide essential education on water, sanitation, and hygiene in a bid to tackle water challenges specific to their communities. Projects include improving access to safe water in underserved communities in Buenos Aires and Cape Coast, building flood-resilient communities in Mexico City and Kuala Lumpur, and advancing water sustainability education in Melbourne.
The top-voted project will win the opportunity for young leaders to experience a once-in-a-lifetime trip to the Etihad Stadium. There, they will learn more about water challenges and solutions, and receive further training on how they can help improve the health and well-being of young people in their communities. Each of the Water Heroes Academy projects will receive funding, educational tools, training, and mentoring from Xylem and Cityzens Giving, providing young leaders the resources needed to create their own unique programs going forward.
The Water Heroes Academy is a joint initiative by Cityzens Giving and Xylem that aims to positively impact 20,000 young people over the next four years. Last year, the program engaged more than 75 young water leaders and delivered vital education to more than 6,000 young people in São Paulo, Mumbai, Cape Town, New York City, and Shanghai. Mumbai was the winning project, having received thousands of fan votes. Delivered in collaboration with Magic Bus India Foundation, the project aimed to improve local access to safe water, sanitation, and hygiene.
“In my community, many children aren’t able to access clean water in school, which means they fall ill and can no longer attend class due to poor health,” said Varsha, a Young Leader from the Mumbai Team. “The opportunity to better the lives of people in my community through awareness and education motivates me. I’m incredibly proud to contribute to the development of my community and make a positive difference in the lives of young people through my experience with the Water Heroes Academy.”
“We’re thrilled to be working with Xylem to spotlight five more of our inspiring Water Heroes Academy projects around the world, celebrating our Cityzens Giving young leaders who are all making such an important impact in their local communities,” said Tom Pitchon, Global Foundation Director at City Football Group. “It was fantastic to welcome our Mumbai water heroes to Manchester last season, and we look forward to welcoming young leaders from the top-voted project this year, so vote now!”
“We are incredibly proud of our partnership with Manchester City and the global network of young water leaders created through the Water Heroes Academy program,” said Randolf Waters, Senior Director of Global Partnerships & Branding at Xylem. “In spotlighting the work these incredible water leaders are doing locally, we hope to inspire more young people to get involved in tackling water issues and drive positive change on a global level. I encourage football fans to get behind our water heroes and vote for their favorite project.”
To hear the story of each project and to vote for your top project, visit: www.mancity.com/waterheroes
About Xylem
Xylem (XYL) is a leading global water technology company committed to solving critical water and infrastructure challenges with innovation. Our 17,000 diverse employees delivered revenue of $5.2 billion in 2021. We are creating a more sustainable world by enabling our customers to optimize water and resource management and helping communities in more than 150 countries become water secure. Join us at www.xylem.com.
About Manchester City Football Club
Manchester City FC is an English Premier League club initially founded in 1880 as St Mark’s West Gorton. It officially became Manchester City FC in 1894 and has since then gone onto win the European Cup Winners’ Cup, eight League Championship titles, including six Premier League titles (2012, 2014, 2018, 2019, 2021, 2022), and six FA Cups. Manchester City FC is one of 12 clubs comprising the City Football Group and counts New York City FC and Melbourne City FC among its sister clubs.
Under manager Pep Guardiola, one of the most highly-decorated managers in world football, the Club plays its domestic and UEFA Champions League home fixtures at the Etihad Stadium, a spectacular 55,000 seat arena that City have called home since 2003. Today, the Stadium sits on the wider Etihad Campus, which also encompasses the City Football Academy, a state-of-the-art performance training and youth development facility located in the heart of East Manchester. Featuring a 7,000 capacity Academy Stadium, the City Football Academy is also where Manchester City Women’s Football Club and the Elite Development Squad train on a daily basis and play their competitive home games.
For more information, please visit www.mancity.com.
About Cityzens Giving
Cityzens Giving is an award-winning global programme, empowering young leaders to use football as a tool to uplift the health of children and young people in cities around the world. Projects are run by young people for young people, with fans, staff and partners across City Football Group getting involved in diverse ways, from volunteering and fundraising to donating and having a say in how projects are supported. In addition to long-term grant funding, young leaders access training in community football and leadership from our Club community coaches and networking opportunities with other community football projects worldwide. This includes face to face training in country, remote support, and regular global gatherings to facilitate the flow of know-how and learning. Each year, Cityzens Giving supports over 1,000 Young Leaders to positively impact the health of thousands of young people in 25 cities across the globe.
For more information, please visit https://www.mancity.com/community/global-projects.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221122005464/en/
Contact information
Houston Spencer
+1 (914) 240-3046
Houston.Spencer@xylem.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 01:00:00 EET | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemia (CLL), highlighting the foundational potential of this medicine. “The data we’re presenting at ASH 2025 are redefining what physicians can expect from sonrotoclax as a next-generation BCL2 inhibitor,” said Amit Agarwal, M.D., Ph.D., Chief Medical
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 18:00:00 EET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 14:00:00 EET | Press release
Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships Powering the Summit CoMotion GLOBAL 2025 is hosted by the Saudi Conventions & Exhibitions General Authority (SCEGA), supported by key Saudi
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release
Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release
Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
